AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26665289 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm & Hammer Truly Radiant Rejuvenating toothpaste
Number of subjects: 54
Study 26665289 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cavity Protection toothpaste (negative control)
Number of subjects: 54
Study 23995858 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1970
Study 23995858 — intervention group
Group type: COMPARATOR
Intervention: CTD (cyclophosphamide-thalidomide-dexamethasone)
Number of subjects: 1970
Study 23995858 — intervention group
Group type: EXPERIMENTAL
Intervention: CTDa (attenuated CTD)
Number of subjects: 1970
Study 23995858 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide maintenance
Number of subjects: 1970
Study 21104485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 30
Study 21104485 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEAR NPT
Number of subjects: 30
Study 19452709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 69
Study 19452709 — intervention group
Group type: COMPARATOR
Intervention: loratadine
Number of subjects: 69
Study 17908564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Number of subjects: 12
Study 17908564 — intervention group
Group type: COMPARATOR
Intervention: Sitting astride a Bobath roll
Number of subjects: 12
Study 17908564 — intervention group
Group type: COMPARATOR
Intervention: Sitting on a stool with rocking seat
Number of subjects: 12
Study 17908564 — intervention group
Group type: COMPARATOR
Intervention: Control condition (spasticity measurement without intervention)
Number of subjects: 12
Study 15215018 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 1380
Study 15215018 — intervention group
Group type: COMPARATOR
Intervention: Abdominal laparoscopic hysterectomy (ALH)
Number of subjects: 1380
Study 15215018 — intervention group
Group type: COMPARATOR
Intervention: Vaginal laparoscopic hysterectomy (VLH)
Number of subjects: 1380
Study 15215018 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard abdominal hysterectomy (AH)
Number of subjects: 1380
Study 11234182 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly home fructosamine monitoring in addition to daily glucose monitoring
Number of subjects: 140
Study 11234182 — intervention group
Group type: COMPARATOR
Intervention: Daily glucose monitoring only (Control)
Number of subjects: 140
Study 15034317 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (600 mg/day for 12 months)
Number of subjects: 74
Study 15034317 — intervention group
Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 74
Study 8359567 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 27
Study 8359567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8359567 — intervention group
Group type: COMPARATOR
Intervention: Historical series
Number of subjects: 27
Study 3706881 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol
Number of subjects: 8
Study 3706881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered aminophylline (17.0 to 22.4 mg/L)
Number of subjects: 8
Study 3706881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered aminophylline plus inhaled isoproterenol
Number of subjects: 8
Study 3706881 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered placebo
Number of subjects: 8
Study 31939515 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 78
Study 31939515 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS or WhatsApp
Number of subjects: 78
Study 31939515 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 78
Study 29868973 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal oxygenation group (SpO2 targets > 94%)
Number of subjects: 159
Study 29868973 — intervention group
Group type: COMPARATOR
Intervention: Conservative oxygenation group (SpO2 = 88-92%)
Number of subjects: 159
Study 27513475 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online gratitude intervention
Number of subjects: 67
Study 27513475 — intervention group
Group type: COMPARATOR
Intervention: 6-week online control condition
Number of subjects: 67
Study 25088739 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors implanted in 242 patients (75.9%) during initial EVAR procedure
Number of subjects: 319
Study 25088739 — intervention group
Group type: COMPARATOR
Intervention: EndoAnchors implanted in 77 patients with existing endograft and proximal aortic neck complications
Number of subjects: 319
Study 25088739 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors used prophylactically in patients with hostile aortic neck anatomy
Number of subjects: 319
Study 22362838 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention group
Number of subjects: 0
Study 22362838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Full screening intervention
Number of subjects: 0
Study 21036822 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened ceilings intervention
Number of subjects: 0
Study 21036822 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 0
Study 18395345 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 520
Study 18395345 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 520
Study 18395345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 15918560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and/or radiotherapy
Number of subjects: 0
Study 15918560 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 0
Study 11909787 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 600
Study 11909787 — intervention group
Group type: COMPARATOR
Intervention: Optimised insulin injections
Number of subjects: 600
Study 12377361 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session guided self-change treatment
Number of subjects: 93
Study 12377361 — intervention group
Group type: COMPARATOR
Intervention: One-session advice treatment
Number of subjects: 93
Study 9846012 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-oriented individualized induction therapy with six drugs (doxorubicin, mitoxantrone, vincristine, prednisolone, cyclophosphamide, L-asparaginase)
Number of subjects: 180
Study 9846012 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (allo-BMT)
Number of subjects: 180
Study 9846012 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with leukocytes < 30,000/microliter and blasts < 10% on day 15
Number of subjects: 180
Study 9846012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results compared to former ALL87 protocol
Number of subjects: 180
Study 9846012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with good prognostic factors (leukocyte < 30,000/microliter and age < 30 years old)
Number of subjects: 180
Study 7854594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml/kg ethanol
Number of subjects: 10
Study 7854594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2509264 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diazepam
Number of subjects: 186
Study 2509264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 186
Study 2509264 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 186
Study 2509264 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic treatment (sodium valproate or phenobarbitone)
Number of subjects: 186
Study 807007 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral 1.75 per cent L‐essential amino acids in 47 per cent dextrose (Group I)
Number of subjects: 20
Study 807007 — intervention group
Group type: COMPARATOR
Intervention: 47 per cent dextrose (Group II)
Number of subjects: 20
Study 31574511 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% TAAC poloxamer 407 hydrogel
Number of subjects: 3
Study 31574511 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% TAAC hydrogel
Number of subjects: 3
Study 31574511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 28318451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate administered 10 days per month for 3 months
Number of subjects: 0
Study 28318451 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25231114 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care nerve conduction device (POCD; NC-stat®|DPNCheck™)
Number of subjects: 162
Study 25231114 — intervention group
Group type: COMPARATOR
Intervention: LDIFLARE technique
Number of subjects: 162
Study 23167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 446
Study 23167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 446
Study 23167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 446
Study 23167925 — intervention group
Group type: COMPARATOR
Intervention: Ethosuximide and Valproic acid
Number of subjects: 446
Study 22082582 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stent trials (1995-1997)
Number of subjects: 10253
Study 22082582 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stent trials (1998-2002)
Number of subjects: 10253
Study 22082582 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stent trials (2003-2006)
Number of subjects: 10253
Study 19420182 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-dosed atomoxetine
Number of subjects: 288
Study 19420182 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dosed atomoxetine
Number of subjects: 288
Study 19420182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 16485883 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diclofenac sodium gel used for 90 days
Number of subjects: 30
Study 16485883 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-fluorouracil cream used for 28 days
Number of subjects: 30
Study 15344544 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (methods include Endoluminal Gastroplication, Full Thickness Plicator, Stretta, Enteryx, Gatekeeper)
Number of subjects: 0
Study 15344544 — intervention group
Group type: COMPARATOR
Intervention: Medication and laparoscopic antireflux surgery
Number of subjects: 0
Study 10645920 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibody levels to herpes simplex type I (HSV‐1)
Number of subjects: 241
Study 10645920 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibody levels to Chlamydia pneumoniae (Cpn)
Number of subjects: 241
Study 10645920 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP) levels
Number of subjects: 241
Study 10645920 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint effect of high antibody levels to HSV‐1 and Cpn
Number of subjects: 241
Study 10645920 — intervention group
Group type: COMPARATOR
Intervention: Low antibody levels and low CRP
Number of subjects: 241
Study 9080161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator (Harvey 1700)
Number of subjects: 61
Study 9080161 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (Cobe CML)
Number of subjects: 61
Study 9080161 — intervention group
Group type: COMPARATOR
Intervention: Both oxygenators
Number of subjects: 61
Study 8436156 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg and 100 mg)
Number of subjects: 10
Study 8436156 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine (100 mg and 200 mg)
Number of subjects: 10
Study 8436156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30699060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% ophthalmic solution (BID, n = 90)
Number of subjects: 300
Study 30699060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% ophthalmic solution (TID, n = 76)
Number of subjects: 300
Study 30699060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% ophthalmic solution (QID, n = 68)
Number of subjects: 300
Study 30699060 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% TID (n = 82)
Number of subjects: 300
Study 30699060 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% TID (n = 72)
Number of subjects: 300
Study 28857945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted motivational interviewing (MI)
Number of subjects: 276
Study 28857945 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine explanation by an ophthalmologist and an educational pamphlet)
Number of subjects: 276
Study 25082710 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation scenarios on cardiac arrhythmia
Number of subjects: 91
Study 25082710 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture on cardiac arrhythmia
Number of subjects: 91
Study 23391599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol (PP) group
Number of subjects: 220
Study 23391599 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-prophylactic paracetamol (NPP) group
Number of subjects: 220
Study 23391599 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprimed children)
Number of subjects: 220
Study 22023417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided DPNB
Number of subjects: 66
Study 22023417 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark technique DPNB
Number of subjects: 66
Study 19860305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 19860305 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 19860305 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17477886 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/d for 42 days
Number of subjects: 15
Study 14977803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg p.o. preoperatively followed by placebo
Number of subjects: 50
Study 14977803 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg p.o. (three doses)
Number of subjects: 50
Study 11824249 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental resection and endoscopic surveillance
Number of subjects: 0
Study 11824249 — intervention group
Group type: COMPARATOR
Intervention: Extended prophylactic surgery
Number of subjects: 0
Study 9786475 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of DW-116 (100, 200, 300, and 800 mg)
Number of subjects: 0
Study 9786475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of DW-116 (300 mg for 7 days)
Number of subjects: 0
Study 9786475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of DW-116 (400 mg for 7 days)
Number of subjects: 0
Study 9786475 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple dosing of DW-116
Number of subjects: 0
Study 9786475 — intervention group
Group type: EXPERIMENTAL
Intervention: DW-116 taken before a high-fat breakfast
Number of subjects: 0
Study 8147929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injections of hyaluronan (2.5 ml, weekly for 5 weeks)
Number of subjects: 52
Study 8147929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle, saline)
Number of subjects: 52
Study 3256414 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating a 3100 kJ cold meal
Number of subjects: 8
Study 3256414 — intervention group
Group type: COMPARATOR
Intervention: Auscultation method (Korotkoff I, IV, and V)
Number of subjects: 8
Study 3256414 — intervention group
Group type: COMPARATOR
Intervention: Automated device with a microphone over the brachial artery
Number of subjects: 8
Study 3256414 — intervention group
Group type: COMPARATOR
Intervention: Graphical analysis of microphone signals
Number of subjects: 8
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/day
Number of subjects: 2558
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5 mg/day
Number of subjects: 2558
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (dose range 1.5-6 mg/day for schizophrenia and 3-6 mg/day for bipolar mania)
Number of subjects: 2558
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (dose increase)
Number of subjects: 2558
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cariprazine exposures
Number of subjects: 2558
Study 31664765 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-weighted cariprazine exposures
Number of subjects: 2558
Study 29890298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting sleep and pain catastrophizing
Number of subjects: 156
Study 29890298 — intervention group
Group type: EXPERIMENTAL
Intervention: Helplessness component of catastrophizing and insomnia severity
Number of subjects: 156
Study 29890298 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting pain-related helplessness
Number of subjects: 156
Study 28395915 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus
Number of subjects: 106
Study 28395915 — intervention group
Group type: COMPARATOR
Intervention: No Bolus
Number of subjects: 106
Study 25751176 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Basic Care Management (PBCM) program
Number of subjects: 99
Study 25751176 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 99
Study 23009037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vision lenses with full correction
Number of subjects: 200
Study 23009037 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses with undercorrection of +0.50 D
Number of subjects: 200
Study 20497513 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM-matched PLTs
Number of subjects: 9
Study 20497513 — intervention group
Group type: COMPARATOR
Intervention: CREG-matched PLTs
Number of subjects: 9
Study 20497513 — intervention group
Group type: COMPARATOR
Intervention: A/BU-matched PLTs
Number of subjects: 9
Study 18617483 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-pro-BNP ≥ 9252 pg/mL (fourth quartile)
Number of subjects: 1255
Study 18617483 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of NT-pro-BNP
Number of subjects: 1255
Study 18617483 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in NT-pro-BNP
Number of subjects: 1255
Study 18617483 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline or change in NT-pro-BNP
Number of subjects: 1255
Study 16416313 — intervention group
Group type: EXPERIMENTAL
Intervention: S447X allele carriers
Number of subjects: 146
Study 14560895 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11973949 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 12
Study 11973949 — intervention group
Group type: COMPARATOR
Intervention: Placebo reflexology
Number of subjects: 12
Study 9036439 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 10
Study 9036439 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 10
Study 1728070 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose IVN (36 kcal.kg-1.day-1)
Number of subjects: 20
Study 1728070 — intervention group
Group type: COMPARATOR
Intervention: Lipid IVN (37 kcal.kg-1.day-1)
Number of subjects: 20
Study 6420831 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 0
Study 6420831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoridazine
Number of subjects: 0
Study 6420831 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine plus metabolites
Number of subjects: 0
Study 30806695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Care Transitions in HF transitional care model (n = 1104 patients)
Number of subjects: 2494
Study 29069041 — intervention group
Group type: COMPARATOR
Intervention: Fiber-free nutrition formula (FF group)
Number of subjects: 120
Study 29069041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-enriched nutrition formula (FE group)
Number of subjects: 120
Study 29069041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber- and probiotic-enriched nutrition formula (FEP group)
Number of subjects: 120
Study 26553705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock news article about NIPS
Number of subjects: 1789
Study 26553705 — intervention group
Group type: COMPARATOR
Intervention: Mock news article about amniocentesis
Number of subjects: 1789
Study 26553705 — intervention group
Group type: COMPARATOR
Intervention: No article
Number of subjects: 1789
Study 25057845 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) on an aquatic treadmill
Number of subjects: 18
Study 21923329 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine solution
Number of subjects: 153
Study 21923329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 20128335 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating massage applied to thigh muscles for 10 min on the affected leg
Number of subjects: 19
Study 20128335 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 19
Study 17218881 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage from student therapists with 950 h of didactic training
Number of subjects: 895
Study 17218881 — intervention group
Group type: COMPARATOR
Intervention: Massage from student therapists with 700 h of didactic training
Number of subjects: 895
Study 17218881 — intervention group
Group type: COMPARATOR
Intervention: Massage from student therapists with 450 h of didactic training
Number of subjects: 895
Study 15114391 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing with one lead via coronary sinus and one lead endocardially at the apex of the right ventricle
Number of subjects: 0
Study 15114391 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing combined with cardioverter defibrillator units
Number of subjects: 0